PresbyopiaNCT06963138
Comparative Study and Validation of New Methodologies for Measuring Addition
A study testing Visual Acuity, Objective refraction and Standard Subjective refraction in people with Presbyopia and Near Vision, run by Essilor International at 1 site in France.
Trial summary
The aim of this research is to collect comprehensive data on a presbyopic population that may require near vision correction, in order to identify the most useful tests to accurately determine the value of an addition. Read more about this study
- Who is it for?
- Ages 40 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Presbyopia, Near Vision, Refraction Error
- What is being tested?
- Visual Acuity, Objective refraction and Standard Subjective refraction
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteFrance
- Study dates
- 31 Mar 2025to 5 May 2025
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Volunteer, fluent in French, willing to follow the protocol, able to read and understand the information form and give free and informed consent
- Aged 40 to 60 years
- Individual with monocular visual acuity ≥ +0.1 LogMAR with current corrections and pinhole if necessary
- Individual with a visual acuity difference ≤ 0.2 LogMAR with current corrections
- Individual with stable binocular vision in distance and near vision
Who cannot join
- Age < 40 years (i.e., no minors in accordance with Article L1121-7)
- Age > 60 years
- All categories of people specifically protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the Public Health Code):
- Pregnant, childbearing, or breastfeeding women (Article L1121-5)
- Persons deprived of their liberty by a judicial or administrative decision and persons hospitalized without consent pursuant to Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8 and persons admitted to a health or social care facility for purposes other than research
- Adults incapable or unable to express consent (Article L1121-8)
Show all 14Show fewer
- Participants currently excluded from another study
- Participants unable to be contacted in case of emergency
- Person with strabismus
- Person with amblyopia
- Aphakic or pseudophakic person
- Person with vertical phoria > 1 PD
- Declared neurological deficit, including a history of epileptic disorders or sensory-motor coordination disorders, vestibular or cerebellar pathology (e.g., balance disorders)
- Declared severe ocular pathology, involving visual field loss, such as glaucoma, or involving loss of acuity and significant discomfort in dimly or excessively lit environments, such as retinitis pigmentosa, or declared and treated dry eye.
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this research is to collect comprehensive data on a presbyopic population that may require near vision correction, in order to identify the most useful tests to accurately determine the value of an addition.
Read the detailed description
Refraction is the key point of an ophthalmic examination when visual correction is required for distance vision, as is determining the addition for near vision. These measurements can be obtained objectively and/or subjectively.
The addition for near vision is most often obtained using so-called subjective devices, i.e., by relying on the patient's responses.
The state of the accommodative system can, however, be measured objectively using instruments available to prescribers (retinoscopes, automatic refractometers, aberrometers, etc.). These measurements can be used in clinical practice as a solid basis for the initial assessment of the subject's refractive status during a comprehensive eye examination. However, these measurements are not sufficient to determine the optimal correction to prescribe for near vision, i.e., one that achieves sufficient visual acuity and comfort to ensure effectiveness for the tasks a person wishes to perform in their daily life.
Indeed, subjective tests are considered the gold standard for prescribers, particularly when it comes to near vision testing. Also, there are numerous procedures for determining the appropriate addition to prescribe, and a wide variety of practices is observed among prescribers around the world. It is often necessary to perform multiple tests to ensure the correct addition value to recommend.
The aim of this study is to find ways of approaching the value of the ideal addition as accurately as possible, based on several parameters: measurements representative of subjects' near vision habits, optometric measurements to determine near vision addition, and measurements related to binocular vision and symptomatology. This data collection will enable to identify the most effective combination of measurements in order to determine the optimal near vision addition for a subject.
- Conditions
- Presbyopia, Near Vision, Refraction Error
- Being tested
- Visual Acuity, Objective refraction, Standard Subjective refraction, Near vision examination and determination of additions, Binocular vision tests
- Medical subject headings
- Presbyopia, Myopia, Refractive Errors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Visual AcuityDevice
VA will be measured for near and distance vision with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
Objective refractionDevice
Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
Standard Subjective refractionDevice
Standard subjective refraction for distance vision will be performed with Vision-R™
Near vision examination and determination of additionsDevice
Near vision examination and determination of additions will be performed with Vision-R™. The following objective and subjective measurement methods will determine the values of the various additions:
- Determination of addition using the retinoscopy method (Add_OBJ)
- Randomization and administration of addition determination tests: FCC; R/G; PRA-NRA
Binocular vision testsDevice
The following measurements will be taken in trial glasses equipped with the final addition:
- Stereoscopic acuity measurement
- Measurement of the Near Point of Accommodation (PPA)
- Measurement of the Near Point of Convergence (PPC)
- Measurement of fusion reserves
- Measurement of prismatic rock
- Subjective questionnaire on the different methods used
Extended trial of additionDevice
The following measurements will be performed using trial glasses equipped with the final addition:
- Submission of the CISS questionnaire and distance adaptation
- Initial measurements of accommodative positioning and phorias
- Completion of three smartphone tasks: reading, memorization, and video viewing
- Final measurements of accommodative positioning and phorias
- Submission of the QoL questionnaire regarding visual discomfort during the trial.
| Study group | Role | What they receive |
|---|---|---|
| Validation of new addition measurement methodologies | Experimental | Not described Receives: Device: Visual Acuity; Device: Objective refraction; Device: Standard Subjective refraction; Device: Near vision examination and determination of additions; Device: Binocular vision tests; Device: Extended trial of addition |
What is being measured
The primary outcome is the main question the study is designed to answer.
Subject's age
The subject's age is requested via the Case Report Form
Measured: Day 1
Addition value given by the objective method
When you have presbyopia, the lens is no longer able to increase its power to accommodate near vision. It must then be helped by adding power for near vision, i.e., increasing the strength of the lens: this is called addition. The value of the addition is expressed in diopters (D) and is automatically measured by an auto-kerato-refractometer/aberrometer. It is an objective measure because it does not call upon the subject's responses when presented with acuity scales.
Measured: Day 1
Addition value given by the subjective method
When you have presbyopia, the lens is no longer able to increase its power to accommodate near vision. It must then be helped by adding power for near vision, i.e., increasing the strength of the lens: this is called addition. The value of the addition is expressed in diopters (D) and is automatically measured by an autorefractometer. It is a subjective measure because it calls upon the subject's responses when presented with acuity scales.
Measured: Day 1
Working distances for near vision
Several working distances are measured for near vision. The values of the distances are expressed in centimeters (cm).
The various working distances for near vision are:
- Harmon distance: the morphological distance from the elbow to the clenched fist
- Revip distance (visuo-postural reflex): the subject is given a blank A4 sheet of paper and asked to hold it at their potential reading distance.
- Desired distance: the distance at which a subject can read a Times 12 text on an A4 sheet of paper.
Measured: Day 1
Secondary outcomes (2)
Quality of Vision questionnaire (Qov) score
The QoV Questionnaire consists of a Rasch-tested, linear-scaled, 30-item instrument on three scales providing a QoV score in terms of symptom frequency, severity, and bothersome. It is suitable for measuring QoV in patients with all types of refractive correction, eye surgery, and eye disease that cause QoV problems.
The QoV Questionnaire includes, 10 questions for each nature of evaluation (frequency, severity and bothersome) and 4 possible answers weighted by the values 0, 1, 2 or 3. The higher the score, the more frequently or intensely the symptom is perceived, or the more annoying it is, depending on the nature of the evaluation. Minimum score : 0 ; Maximum Score : 30.
Measured: Day 1
CISS questionnaire (Convergence Insufficiency Symptom Survey) score
The CISS Questionnaire consists of a 14-item instrument providing a CISS score in terms of symptom frequency. Convergence Insufficiency is a condition in which a patient finds it difficult to maintain alignment of the eyes on a near object. The assessment of potential convergence difficulties in near vision may cause a person to look with just one eye at a time, or to see double.
The Convergence Insufficiency Symptom Survey includes 5 questions relative to specific visual symptoms, with 5 possible answers weighted by the values 0, 1, 2, 3 or 4. The higher the score, the more frequently the symptom is perceived. Minimum Score : 0 ; Maximum Score : 60.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2025
- Study start31 Mar 2025
- Primary completion5 May 2025
- Study completion5 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PresbyopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Essilor International
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- François Daniel, Principal investigator, ESSILOR INTERNATIONAL - Division Instruments
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06963138
- Sponsor's protocol ID
- WS10331
- Other IDs
- 2023-A00122-43
- Status last verified
- Jun 2025
- First submitted
- 17 Apr 2025
- Last updated
- 6 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No